Imugene is an Australian biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies.
The company has a worldwide exclusive license agreement to develop the Her-Vaxx vaccine that was developed at The Medical University of Vienna. Her-Vaxx has the ability to stimulate the body's immune system to produce Herceptin, which assists in fighting breast and gastric cancer.
Forrest Capital's Role:
Forrest associates were substantial shareholders in the Australian vaccine company Biolife Science Ltd.
- Forrest negotiated the acquisition of Biolife by IMU.
- Conducted associated capital raising totalling $11 million.
- Facilitated the appointment of Dr Axel Hoos, Ms Leslie Chong and Mr Otto Buttula to the company.